VCNX

Vaccinex, Inc. [VCNX] Stock Forecast

Buy or Sell ? Support and Resistance
What is MACD and how to read it?
How RSI can help?
RSI : 000

VCNX Stock Summary

In the News

VCNX Financial details

Company Rating
-
Market Cap
8.69M
Income
-20.23M
Revenue
570K
Book val./share
-
Cash/share
-
Dividend
-
Dividend %
-
Employees
37
Optionable
No
Shortable
Yes
Earnings
13 May 2024
P/E
-0.14
Forward P/E
-
PEG
0.04
P/S
13.38
P/B
-0.77
P/C
-
P/FCF
-0.45
Quick Ratio
0.17
Current Ratio
0.35
Debt / Equity
-
LT Debt / Equity
-
-
-
EPS (TTM)
-64.31
EPS next Y
-
EPS next Q
-
EPS this Y
-55.24%
EPS next Y
-
EPS next 5Y
-
EPS last 5Y
-39.11%
Revenue last 5Y
1.74%
Revenue Q/Q
-
EPS Q/Q
-75.62%
-
-
-
-
SMA20
4.29%
SMA50
-37.61%
SMA100
-78.47%
Inst Own
-
Inst Trans
-
ROA
-857%
ROE
-2657%
ROC
6.05%
Gross Margin
100%
Oper. Margin
-3712%
Profit Margin
-3537%
Payout
-
Shs Outstand
-
Shs Float
-
-
-
-
-
Target Price
-
52W Range
5.87-100.8
52W High
-99.26%
52W Low
-85.2%
RSI
48.78
Rel Volume
0.01
Avg Volume
12.56K
Volume
100
Perf Week
4.23%
Perf Month
-20.43%
Perf Quarter
-72.89%
Perf Half Y
-70.75%
-
-
-
-
Beta
0.701
-
-
Volatility
0.07%, 0.14%
Prev Close
-1.33%
Price
0.74
Change
-1.33%

Something similar

Top by Market Cap
VTI
1YD.DE
CMC.DE
FXAIX
ABEA.DE
Same Sector
206650.KQ
603087.SS
EAR
SBBP
GRCL
Same Price Range
ZKIN
CFX.TO
0218.HK
CFISH.ST
0216.HK
Similar Market Cap
CLDL
ADN
CEW
VRTB
TSOC

Company Profile

Healthcare Biotechnology
  • Volume Average 12.56K
  • Market Capitalization 8.69M
  • Employee 37
  • CEO Dr. Maurice Zauderer Ph.D.
  • Headquarters Rochester,NY,US
  • IPO Date 2018-08-09
  • Website https://www.vaccinex.com

Vaccinex, Inc., a clinical-stage biotechnology company, engages in the discovery and development of targeted biotherapeutics to treat serious diseases and conditions with unmet medical needs. The company offers its products for the treatment of cancer, neurodegenerative diseases, and autoimmune disorders. Its lead product candidate is pepinemab, a humanized monoclonal antibody that completed and planned Phase 1b/2 clinical trials for the treatment of non-small cell lung cancer (NSCLC), head and neck squamous cell carcinoma (HNSCC), Huntington's disease, Alzheimer's disease, osteosarcoma, and melanoma. The company is also developing VX5, a human antibody to CXCL13 that is in preclinical development for the treatment of MS and for other autoimmune disorders. Vaccinex, Inc. was incorporated in 2001 and is headquartered in Rochester, New York.